中华糖尿病杂志
中華糖尿病雜誌
중화당뇨병잡지
CHINES JOURNAL OF DLABETES MELLITUS
2015年
5期
311-315
,共5页
张波%余自成%庄晓明%顾伟鹰%李玉坤%王清%卞茸文%沈建国%杨文英%杨莉
張波%餘自成%莊曉明%顧偉鷹%李玉坤%王清%卞茸文%瀋建國%楊文英%楊莉
장파%여자성%장효명%고위응%리옥곤%왕청%변용문%침건국%양문영%양리
糖尿病,2型%门冬胰岛素30%生活质量%欧洲五维健康量表
糖尿病,2型%門鼕胰島素30%生活質量%歐洲五維健康量錶
당뇨병,2형%문동이도소30%생활질량%구주오유건강량표
Diabetes mellitus,type 2%Biphasic insulin aspart 30%Quality of life%European Quality of Life-5 Dimensions
目的:评估2型糖尿病患者起始或改用门冬胰岛素30治疗后健康相关生活质量(HRQoL)的变化。方法2008年11月至2011年3月,在全国130家研究中心招募起始或改用门冬胰岛素30、地特胰岛素或门冬胰岛素治疗的患者,观察24周的治疗效果,并在基线和24周时采用欧洲五维健康量表(EQ?5D)对患者的HRQoL进行评估。本文报告起始或改用门冬胰岛素30的中国2型糖尿病患者在基线和24周时HRQoL的变化,并进一步分析由口服降糖药转为门冬胰岛素30和由预混人胰岛素转为门冬胰岛素30的亚组人群信息。采用配对t检验、卡方检验等进行统计学分析。结果共纳入8578例中国患者接受门冬胰岛素30治疗。24周后,总体研究人群、由口服降糖药转为门冬胰岛素30组、由预混人胰岛素转为门冬胰岛素30组人群的EQ?5D VAS评分分别增加6分(76至82)、6分(76至82)和7分(75至82),健康效用值分别增加0.018(0.875至0.893)、0.019(0.876至0.894)和0.034(0.845至0.879),前后差异均有统计学意义(t=28.10、19.80、10.90、5.90、4.30、3.90,均P<0.05)。EQ?5D量表的多个维度报告没有问题的患者比例均有所增加。结论血糖控制不佳的中国2型糖尿病患者起始或转用门冬胰岛素30治疗后生活质量显著改善。
目的:評估2型糖尿病患者起始或改用門鼕胰島素30治療後健康相關生活質量(HRQoL)的變化。方法2008年11月至2011年3月,在全國130傢研究中心招募起始或改用門鼕胰島素30、地特胰島素或門鼕胰島素治療的患者,觀察24週的治療效果,併在基線和24週時採用歐洲五維健康量錶(EQ?5D)對患者的HRQoL進行評估。本文報告起始或改用門鼕胰島素30的中國2型糖尿病患者在基線和24週時HRQoL的變化,併進一步分析由口服降糖藥轉為門鼕胰島素30和由預混人胰島素轉為門鼕胰島素30的亞組人群信息。採用配對t檢驗、卡方檢驗等進行統計學分析。結果共納入8578例中國患者接受門鼕胰島素30治療。24週後,總體研究人群、由口服降糖藥轉為門鼕胰島素30組、由預混人胰島素轉為門鼕胰島素30組人群的EQ?5D VAS評分分彆增加6分(76至82)、6分(76至82)和7分(75至82),健康效用值分彆增加0.018(0.875至0.893)、0.019(0.876至0.894)和0.034(0.845至0.879),前後差異均有統計學意義(t=28.10、19.80、10.90、5.90、4.30、3.90,均P<0.05)。EQ?5D量錶的多箇維度報告沒有問題的患者比例均有所增加。結論血糖控製不佳的中國2型糖尿病患者起始或轉用門鼕胰島素30治療後生活質量顯著改善。
목적:평고2형당뇨병환자기시혹개용문동이도소30치료후건강상관생활질량(HRQoL)적변화。방법2008년11월지2011년3월,재전국130가연구중심초모기시혹개용문동이도소30、지특이도소혹문동이도소치료적환자,관찰24주적치료효과,병재기선화24주시채용구주오유건강량표(EQ?5D)대환자적HRQoL진행평고。본문보고기시혹개용문동이도소30적중국2형당뇨병환자재기선화24주시HRQoL적변화,병진일보분석유구복강당약전위문동이도소30화유예혼인이도소전위문동이도소30적아조인군신식。채용배대t검험、잡방검험등진행통계학분석。결과공납입8578례중국환자접수문동이도소30치료。24주후,총체연구인군、유구복강당약전위문동이도소30조、유예혼인이도소전위문동이도소30조인군적EQ?5D VAS평분분별증가6분(76지82)、6분(76지82)화7분(75지82),건강효용치분별증가0.018(0.875지0.893)、0.019(0.876지0.894)화0.034(0.845지0.879),전후차이균유통계학의의(t=28.10、19.80、10.90、5.90、4.30、3.90,균P<0.05)。EQ?5D량표적다개유도보고몰유문제적환자비례균유소증가。결론혈당공제불가적중국2형당뇨병환자기시혹전용문동이도소30치료후생활질량현저개선。
Objective To evaluate the changes of health?related quality of life (HRQoL) in Chinese patients with type 2 diabetes (T2DM) after starting with, or switching to, biphasic insulin aspart 30 (BIAsp 30). Methods From November 2008 to March 2011, eligible T2DM patients, initiating or switching to premix (BIAsp 30), basal (insulin detemir), and meal?time (insulin aspart) insulin analogs, were recruited from 130 hospitals in China. HRQoL was evaluated by European Quality of Life?5 Dimensions (EQ?5D) questionnaire at baseline and 24 weeks. This study reported how HRQoL changed in Chinese people with T2DM after starting with, or switching to, BIAsp 30. Subgroup analyses were conducted. The paired t test, and Chi?square test were conducted for statistical analysis. Results The reported HRQoL measured by EQ?5D visual analogue scale score in total cohort, subgroup switching from oral anti?diabetic drugs (OADs) and subgroup switching from human premix insulin increased by 6.2 (from 75.8 to 82.0), 5.9(from 75.7 to 81.6) and 6.6(from 75.0 to 81.6) respectively;and the EQ?5D index score over 24 weeks increased by 0.018 (from 0.875 to 0.893), 0.019(from 0.876 to 0.894) and 0.034(from 0.845 to 0.879), respectively; all the changes were statically significant (t=28.10, 19.80, 10.90, 5.90, 4.30, 3.90, all P<0.05). The percentage of patients reporting no problems in the mobility, pain/discomfort, and anxiety/depression dimensions of EQ?5D increased to some extent too. Conclusion BIAsp 30 treatment is associated with improved HRQoL in patients with T2DM in China.